investor.sciclone.com
SciClone Pharmaceuticals, Inc. > Calendar of Events
http://investor.sciclone.com/events.cfm
Sciclone at China Conferences. Working at SciClone Corporate. Details on upcoming events are not yet available. Please click here. To be notified of all upcoming events. Aug 9, 2016. Q2 2016 SciClone Pharmaceuticals, Inc. Earnings. May 10, 2016. Q1 2016 SciClone Pharmaceuticals, Inc. Earnings. Apr 13, 2016. 15th Annual Needham Healthcare Conference. Speaker: Wilson W. Cheung, Chief Financial Officer. Mar 10, 2016. Q4 2015 SciClone Pharmaceuticals, Inc. Earnings. Feb 9, 2016. Jan 13, 2016. Jan 11, 2016.
investor.sciclone.com
SciClone Pharmaceuticals and Theravance Biopharma Enter Into Development and Commercialization Agreement for VIBATIV(R) (Telavancin) in China (NASDAQ:SCLN)
http://investor.sciclone.com/releasedetail.cfm?ReleaseID=914990
May 27, 2015. SciClone Pharmaceuticals and Theravance Biopharma Enter Into Development and Commercialization Agreement for VIBATIV(R) (Telavancin) in China. Once-Daily, Dual Mechanism Antibiotic Possesses Profile to Play Key Role in Global Fight Against Antimicrobial Resistance. FOSTER CITY, CA. GEORGE TOWN, GRAND CAYMAN. NASDAQ: SCLN), ("SciClone"), a U.S.-based,. Focused specialty pharmaceutical company, and. Theravance Biopharma, Inc. Potency and a dual mechanism of action whereby telavancin both inhi...
investor.sciclone.com
SciClone Pharmaceuticals, Inc. > Press Room
http://investor.sciclone.com/releases.cfm
Sciclone at China Conferences. Working at SciClone Corporate. Aug 9, 2016. SciClone Reports Second Quarter 2016 Financial Results. FOSTER CITY, Calif., Aug. 9, 2016 /PRNewswire/ - SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported financial results for the quarter ended June 30, 2016. Revenues: In the second quarter of 2016, SciClone reported revenues of $39.0 million, compared to $37.9 million for the same period in 2015. GAAP Diluted EP. Jul 28, 2016. Jul 19, 2016. May 10, 2016. FOSTER CITY, ...
biobiznews.net
Lessons Learned: valor y estrategia | BIOBIZNEWS
https://biobiznews.net/2016/07/10/lessons-learned-valor-y-estrategia
Lessons Learned: valor y estrategia. Qué vale una empresa. 8220;lo que el mercado esté dispuesto a pagar por ella”. Afirma concluyente Lluís Pareras. Director del fondo Healthequity SCR. Pero con productos y tecnologías muy similares, y bases científicas igualmente sólidas, en sus fases iniciales una empresa puede valer en Barcelona. Un tercio o menos de lo que sus homólogas pueden valer en Londres. Simplemente porque la disponibilidad de capital y de inversores es mucho menor. La idea de fondo es que, d...
investor.sciclone.com
SciClone Pharmaceuticals, Inc. > Analyst Coverage
http://investor.sciclone.com/analysts.cfm
Sciclone at China Conferences. Working at SciClone Corporate. SciClone Pharmaceuticals, Inc. is covered by the following analysts. Jerry Isaacson, PhD. Notes Regarding Forward Looking Statements. 24180;赛生制药公司保留所有权利。请阅读我们的免责声明。 使用条款. 27880;意有关前瞻性陈述.
investor.sciclone.com
SciClone Pharmaceuticals, Inc. > Financials & Filings
http://investor.sciclone.com/financials.cfm
Sciclone at China Conferences. Working at SciClone Corporate. SciClone Reports Second Quarter 2016 Financial Results. SciClone Pharmaceuticals, Inc. Annual Report 2015. SciClone Pharmaceuticals, Inc. Proxy Statement. Mar 11, 2016. Mar 12, 2015. Aug 9, 2016. May 10, 2016. Notes Regarding Forward Looking Statements. 27880;意有关前瞻性陈述.
internationalsepsisforum.com
Sponsors - International Sepsis Forum
http://internationalsepsisforum.com/sponsors
Sepsis 20XX Annual Symposia. Stephen F Lowry Colloqiua. World Alliance Against Antibiotic Resistance. The ISF is a registered charity in the US (501(c)(3) and accepts donations from the public to support its activities. If you are interested in supporting the ISF and its educational activities around the world, please contact the ISF Executive Director, Elaine Rinicker, at the address provided on the Contact page. Sepsis 2016: Institut Pasteur: 6-8 December. Sign up for our Email Newsletter.